0
Leap Therapeutics, Inc. Banner Image

Leap Therapeutics, Inc.

  • Ticker LPTX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Leap Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in Cambridge, Massachusetts
Leap Therapeutics (Nasdaq:LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a collaborationMore with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
Leap Therapeutics, Inc.

Most Recent Annual Report

Leap Therapeutics, Inc.
MOST RECENT 2020 Form 10K

Older/Archived Annual Reports